An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications
| Autor: | Douglas W. Grosenbach, Paul G Long, Dennis E. Hruby, Andrew T. Russo, Candace Lovejoy, Ingrid Meara, Biswajit Maiti, Kady M. Honeychurch, Jarasvech Chinsangaram |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) 030106 microbiology Orthopoxvirus Poxviridae Infections Health security Isoindoles Antiviral Agents Microbiology 03 medical and health sciences chemistry.chemical_compound Monkeypox 0302 clinical medicine Virology Humans Medicine Smallpox 030212 general & internal medicine Biodefense biology business.industry Tecovirimat Outbreak medicine.disease biology.organism_classification Bioterrorism Infectious Diseases chemistry Benzamides Vaccinia business |
| Zdroj: | Expert Review of Anti-infective Therapy. 19:331-344 |
| ISSN: | 1744-8336 1478-7210 |
| DOI: | 10.1080/14787210.2020.1819791 |
| Popis: | Tecovirimat (TPOXX®; ST-246) was approved for the treatment of symptomatic smallpox by the USFDA in July of 2018 and has been stockpiled by the US government for use in a smallpox outbreak. While there has not been a reported case of smallpox since 1978 it is still considered a serious bioterrorism threat.A brief history of smallpox from its proposed origins as a human disease through its eradication in the late 20th century is presented. The current smallpox threat and the current public health response plans are described. The discovery, and development of tecovirimat through NDA submission and subsequent approval for treatment of smallpox are discussed. Google Scholar and PubMed were searched over all available dates for relevant publications.Approval of tecovirimat to treat smallpox represents an important milestone in biosecurity preparedness. Incorporating tecovirimat into the CDC smallpox response plan, development of pediatric liquid and intravenous formulations, and approval for post-exposure prophylaxis would provide additional health security benefit.Tecovirimat shows broad efficacy against orthopoxviruses in vitro and in vivo and could be developed for use against emerging orthopoxvirus diseases such as monkeypox, vaccination-associated adverse events, and side effects of vaccinia oncolytic virus therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|